Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. (Record no. 24734355)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02235 a2200625 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517023057.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201506s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1474-5488 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/S1470-2045(15)70082-3 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Pui, Ching-Hon |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20150629 |
| 245 00 - TITLE STATEMENT | |
| Title | Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | The Lancet. Oncology |
| Date of publication, distribution, etc. | Apr 2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 465-74 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adolescent |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Asparaginase |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child, Preschool |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Infant |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Methotrexate |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm Recurrence, Local |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm, Residual |
| General subdivision | chemically induced |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prednisone |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prospective Studies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Remission Induction |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Risk Factors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | United States |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vincristine |
| General subdivision | administration & dosage |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pei, Deqing |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Coustan-Smith, Elaine |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jeha, Sima |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cheng, Cheng |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bowman, W Paul |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sandlund, John T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ribeiro, Raul C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rubnitz, Jeffrey E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Inaba, Hiroto |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bhojwani, Deepa |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gruber, Tanja A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leung, Wing H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Downing, James R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Evans, William E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Relling, Mary V |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Campana, Dario |
| 773 0# - HOST ITEM ENTRY | |
| Title | The Lancet. Oncology |
| Related parts | vol. 16 |
| -- | no. 4 |
| -- | p. 465-74 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/S1470-2045(15)70082-3">https://doi.org/10.1016/S1470-2045(15)70082-3</a> |
| Public note | Available from publisher's website |
No items available.